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Abstract Background A poor ability of recommended risk scores for predicting in-hospital
bleeding has been reported in elderly patients with acute coronary syndromes (ACS).
No study assessed the prediction of post-discharge bleeding in the elderly. The new
BleeMACS score (Bleeding complications in a Multicenter registry of patients dis-
charged with diagnosis of Acute Coronary Syndrome), was designed to predict post-
discharge bleeding in ACS patients. We aimed to assess the predictive ability of the
BleeMACS score in elderly patients.
Methods Weassessed the incidence andcharacteristics of severebleedingafter discharge
in ACS patients aged  75 years. Bleeding was defined as any intracranial bleeding or
bleeding leading to hospitalization and/or red blood transfusion, occurring within the first
year after discharge. We assessed the predictive ability of the BleeMACS score according to
age by Fine–Gray proportional hazards regression analysis, calculating receiver-operating
characteristic (ROC) curves and the area under the ROC curves (AUC).
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Introduction
Dual antiplatelet therapy (DAPT) with aspirin and an oral
P2Y12 receptor blocker is the standard regimen to prevent
atherothrombotic events in patients after acute coronary
syndromes (ACS).1,2 Antiplatelet drugs decrease the rate of
ischaemic events in patients with ACS, but with a significant
increase in the rate of bleeding.3 There is strong evidence
about the association between bleeding complications and
increasedmortality in this scenario.4 Therefore, bleeding risk
is the limiting factor for the choice of the type and duration of
DAPT after discharge in patients with ACS.
While several bleeding scores5–7havebeen developed and
widely used for the prediction of in-hospital bleeding, little
information exists about the prediction of bleeding after
discharge in this setting. The BleeMACS registry8 (Bleeding
complications in a Multicenter registry of patients dis-
charged with diagnosis of Acute Coronary Syndrome) was
conducted to develop and validate a score to predict post-
discharge bleeding in patients with ACS. This score exhibited
a good ability for predicting serious bleeding 1 year after
discharge in an extensive series of patients with ACS.
On the other hand, incidence of ACS increaseswith age, and
it is particularly high in elderly patients.9,10 These patients are
at higher risk both for ischaemic and bleeding complications,
prolonged hospital stay and increased consumption of health
resources.11Elderlyarepoorly represented inclinical trials and
registries from whom currently recommended bleeding risk
scores were developed. In fact, a poorer predictive ability of
these bleeding risk scores for predicting in-hospital bleeding
has been reported in elderly patients with ACS.12 To our
knowledge, no studyassessed the prediction of post-discharge
bleeding in elderly patients with ACS.
Therefore, the aim of this sub-study was to analyse, in the
BleeMACS database, the incidence and characteristics of
bleeding complications after medical discharge according
to age, and to assess the predictive ability of the BleeMACS
score in elderly patients as compared with the younger
population.
Methods
This study is a sub-analysis of the international multi-centre
BleeMACS registry. Full study protocol has been already
published.13 In brief, the BleeMACS registry enrolled
15,401 consecutive patients undergoing percutaneous cor-
onary intervention (PCI) for ACS, including ST-elevation
myocardial infarction (STEMI), non-STEMI (NSTEMI) and
unstable angina (UA). Recruitment was conducted between
2003 and 2014 in 15 hospital centres from 10 countries from
North America (Canada), South America (Brazil), Europe
(Germany, Poland, Netherlands, Spain, Italy, Greece) and
Asia (China and Japan). DAPTwas prescribed during at least
12 months, except in patients treated with oral anticoagu-
lants, in whom antiplatelet therapy was prescribed based on
clinical judgment of the responsible physician. Baseline
clinical characteristics, in-hospital procedures and adverse
events were recorded for all patients.
A one-year follow-up after the discharge from index
hospitalization was conducted and data about vital status,
bleeding complications, cardiovascular events and other
adverse events were collected from hospital records, by
telephonic contact with patients or their relatives or their
primary care physician if deemed necessary.
The primary end-point of the study was the incidence of
serious bleeding complications within the first year after
hospital discharge, defined as intracranial bleeding or any
other bleeding leading to hospitalization and/or red blood
cell transfusion. Bleeding and/or red blood transfusions
related to procedures or surgeries were not considered for
the purpose of this study.
TheBleeMACS score8was compoundby seven independent
predictors of bleeding (age, hypertension, vascular disease,
history of bleeding, malignancy, creatinine and haemoglobin).
The score was developed by assigning a weighted integer to
each independent predictoron thebasisof its coefficient in the
final model. A point score for each patient was calculated by
summing the weighted integers (►Table 1). Patients were
classified further into quartiles of the BleeMACS risk score:
very low-risk ( 7 points), low-risk (8–16 points), moderate-
risk (17–24 points) and high-risk ( 25 points). This risk score
exhibited a good ability for predicting spontaneous serious
bleeding after discharge (c-statistic value of 0.71 in the deriva-
tion cohort and 0.72 in the internal validation sample).
Definitions
NSTEMI was defined as the presence of chest pain in the
previous 48 hours accompanied by electrocardiographic
Results The BleeMACS registry included 15,401 patients of whom 3,376/15,401
(21.9%) were aged  75 years. Elderly patients were more commonly treated with
clopidogrel and less often treated with ticagrelor or prasugrel. Of 3,376 elderly
patients, 190 (5.6%) experienced post-discharge bleeding. The incidence of bleeding
was moderately higher in elderly patients (hazard ratio [HR], 2.31, 95% confidence
interval [CI], 1.92–2.77). The predictive ability of the BleeMACS score was moderately
lower in elderly patients (AUC, 0.652 vs. 0.691, p ¼ 0.001).
Conclusion Elderly patients with ACS had a significantly higher incidence of post-
discharge bleeding. Despite a lower predictive ability in older patients, the BleeMACS
score exhibited an acceptable performance in these patients.
Thrombosis and Haemostasis Vol. 118 No. 5/2018
Prediction of Post-Discharge Bleeding in Elderly Patients Garay et al.930
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i T
or
in
o.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
abnormalities suggestive of ischaemia or blood troponin
value above the higher normal laboratory limit. STEMI was
defined as chest painwith persistent ST-segment elevation of
0.1 mV or more in at least two contiguous leads or new left
bundle branch block in the electrocardiogram.
Hypertension was defined as prior history of diagnosed
and/or treated hypertension. Vascular disease included prior
stroke/transient ischaemic attack, and/or peripheral artery
disease (in the external validation dataset, vascular disease
was defined as stroke and/or peripheral artery disease,
because data on transient ischaemic attack were not avail-
able). Malignancy was defined as any active cancer or any
non-active cancer treated during the past 3 years of the index
ACS. History of bleeding included any hospitalization due to a
bleeding event prior to the qualifying ACS and/or any serious
bleeding occurring during hospitalization for the index ACS.
For the purpose of this study, elderly patientswere defined as
patients aged 75 years or older.
Statistical Analysis
Categorical variables were expressed as number and percen-
tage. Quantitative variables were expressed as mean and
standard deviation. The variables with non-normal distribu-
tion were expressed as median and interquartile range.
Analysis of the normality of the distribution was conducted
by the Kolmogorov–Smirnoff test. Comparisons between
categorical variables were performed with the chi-square
test or Fisher’s exact test, when appropriate. Comparisons
between quantitative variables were performed with the
Student’s t-test.
The performance of the BleeMACS risk score was assessed
using the Fine–Gray proportional hazards regression analy-
sis,14 using a competing risk framework for bleeding occur-
rence—accounting for death as a competing episode.
The proportional hazard assumption was confirmed by
testing for time-by-covariate interaction in the multivariate
analysis, and the adjusted hazard of bleeding was expressed
as sub-hazard ratios (sHRs) with their corresponding 95%
confidence intervals (95% CIs). The adjusted rate of 1-year
bleeding was calculated and reported as cumulative inci-
dence function (CIF).
Additionally, the ability of the BleeMACS score for pre-
dicting the composite of post-discharge serious bleeding or
death was assessed by a Cox regression model.
The performance of the BleeMACS score according to age
status was tested assessing its discrimination separately in
elderly patients and young patients from the BleeMACS
database. Discrimination was evaluated by calculating the
area under the receiver-operating characteristic (ROC) curve
(AUC), and by assessing CIF curves between the four estab-
lished BleeMACS score risk categories. The AUCs between
elderly and young patients were compared using the DeLong
method.15 A two-sided p-value equal to or less than 0.05 was
considered as statistically significant.
Finally, a predictive model for post-discharge bleeding
was built specifically in patients aged 75 years or older. This
analysis was also performed using the Fine–Gray propor-
tional hazards regression model, considering death as a
competing episode. Variables included in the multivariate
analysis were those with an association (p < 0.05) with
bleeding in univariate analysis. The best model was selected
taking into account the criteria of the best AUC.
All analyses were undertaken using the statistical soft-
ware PASW Statistics 18 and the STATA 14.1 version.
Results
The BleeMACS registry included 15,401 patients, of whom
11,809 (76.7%) were male. Mean age was 63.6 (12.7) years,
and 3,376/15,401 patients (21.9%) were aged 75 years or
older. The characteristics of patients according to age are
shown in ►Table 2.
Patients aged 75 years or older were less often males and
hadahigherprevalenceofcardiovascular risk factors andother
comorbidities, suchasprevious stroke,malignancyorprevious
bleeding. These patients had significantly lower glomerular
filtration and lower haemoglobin values at admission as
compared with younger patients. In addition, clinical presen-
tation with STEMI was less common in the elderly. Older
patients had also poorer left ventricular ejection fraction
and more severe coronary artery disease as compared with
the rest of the patients. Bleeding complications, need for
transfusion, heart failure and reinfarction during hospitaliza-
tion were more common in patients aged 75 years or older.
Significant differenceswere also observed regarding post-
discharge antithrombotic treatment according to age sub-
groups (►Table 3). Elderly patients were more commonly
treated with clopidogrel and less often treated with ticagre-
lor or prasugrel. Oral anticoagulants were more commonly
prescribed in the elderly. Triple therapy was also more
Table 1 Composition of the BleeMACS score
BleeMACS score Points
Age < 67.0 0
67.0–74.9 7
 75 9
Hypertension 7
Vascular disease 6
History of bleeding 19
Malignancy 8
Creatinine mg/dL or mmol/L
<1.0, < 88.4 0
1–1.49, 88.4–131.9 3
1.5, 132.0 12
Haemoglobin g/dL
< 11.0 18
11–13.9 9
> 14.0 0
Abbreviation: BleeMACS score, Bleeding complications in a Multicenter
registry of patients discharged with diagnosis of Acute Coronary
Syndrome score.
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commonly used in older patients. Beta-blockers and statins
were less commonly used in older patients. No significant
differences were observed regarding the use of angiotensin-
converting enzyme (ACE) inhibitors or angiotensin receptor
(AR) blockers.
Post-Discharge Bleeding
During 1-year follow-up, 489/15,401 patients (3.2%) pre-
sented serious spontaneous bleeding. The incidence of
bleeding episodes was moderately higher in elderly patients
(HR, 2.31, 95% CI, 1.92–2.77, p < 0.001, ►Fig. 1).
Table 2 Baseline clinical characteristics and in-hospital clinical course according to age sub-groups
Elderly patients
(n ¼ 3,376)
Young patients
(n ¼ 12,025)
p-Value
Continent 0.001
Europe 2,471 (73.2) 7,533 (62.6)
Asia 421 (12.5) 1,911 (15.9)
North America 465 (13.8) 2,477 (20.6)
South America 19 (0.6) 104 (0.9)
Age 80.6 (4) 58.9 (10) 0.001
Male sex 2,002 (59.3) 9,807 (81.6) 0.001
Hypertension 2,475 (73.3) 6,561 (54.6) 0.001
Diabetes mellitus 981 (29.1) 2,718 (22.6) 0.001
Dyslipidaemia 1,597 (47.6) 6,426 (53.9) 0.001
Previous MI 524 (15.5) 1,318 (11) 0.001
Previous PCI 494 (14.7) 1,427 (12) 0.001
Previous CABG 171 (5.1) 340 (2.8) 0.001
Previous stroke 384 (11.4) 523 (4.3) 0.001
PAD 326 (9.7) 580 (4.8) 0.001
CHF 202 (6.6) 246 (2.3) 0.001
Malignancy 383 (11.3) 543 (4.5) 0.001
Previous bleeding 260 (7.8) 540 (4.5) 0.001
LVEF 52 (12) 54 (11) 0.001
Haemoglobin at admission 13 (2) 14.3 (2) 0.001
Haemoglobin at discharge 11.9 (2) 13.4 (3) 0.001
Creatinine at admission 1.07 (0.6) 0.92 (0.5) 0.001
STEMI 1,671 (49.5) 7,266 (60.4) 0.001
UA 484 (14.3) 1,574 (13.1) 0.032
Killip class II or higher 631 (22.3) 1,016 (11) 0.001
Femoral access 1,765 (60) 6,370 (57.8) 0.037
Multi-vessel disease 1,424 (57.4) 3,922 (45.9) 0.001
DES 1,153 (34.2) 4,891 (40.7) 0.001
Thrombolysis 29 (0.9) 210 (1.7) 0.001
Complete revascularization 1,402 (52.5) 5,647 (62.3) 0.001
In-hospital bleeding 365 (10.8) 554 (4.6) 0.001
In-hospital transfusion 213 (6.6) 252 (2.3) 0.001
In-hospital reinfarction 59 (1.8) 141 (1.2) 0.011
In-hospital heart failure 209 (6.9) 376 (3.6) 0.001
BleeMACS score 27 (11) 12 (10) 0.001
Abbreviations: BleeMACS score, Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome
score; CABG, coronary artery bypass grafting; CHF, congestive heart failure; DES, drug eluting stents; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA,
unstable angina.
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Mean time to bleeding episodes was significantly shorter
in the elderly (134 days [95% CI, 119–149] vs. 159 days [95%
CI, 147–171], p < 0.001). No significant differences regard-
ing bleeding location according to age sub-groups were
observed. Themost common locationswere gastrointestinal,
genitourinary and intracranial in both groups (►Fig. 2).
Clinical Characteristics and Antithrombotic
Management According to Post-Discharge Bleeding in
Elderly Patients
Clinical characteristics according to post-discharge bleeding
status in elderly patients are shown in ►Table 4. Some
comorbidities such as congestive heart failure, malignancy
and previous bleeding were more common in patients who
presented post-discharge bleeding. These patients had worse
Killipclass at admission, lower left ventricularejection fraction
andmore severe coronary artery disease. In addition, patients
with post-discharge bleeding had lower haemoglobin value at
admission, poorer renal function and higher incidence of in-
hospital bleeding and need for transfusion.
On the other hand, post-discharge use of clopidogrel was
less common and use of ticagrelor was more common in
patients who presented post-discharge 1 year bleeding epi-
sodes. No significant differences were observed regarding
the post-discharge use of the rest of treatments (►Table 5).
Predictive Ability According to Age
The abilityof the BleeMACS score for predicting post-discharge
bleedingwasmoderately lower inelderlypatients ascompared
with the rest (AUC, 0.652 [95% CI, 0.624–0.679] vs. 0.691 [95%
Table 3 Post-discharge treatment according to age sub-groups
Elderly patients
(n ¼ 3,376)
Young patients
(n ¼ 12,025)
p-Value
Aspirin 3,312 (98.1) 11,898 (98.9) 0.001
Clopidogrel 3,071 (91) 10,334 (85.9) 0.001
Ticagrelor 107 (3.2) 524 (4.4) 0.002
Prasugrel 24 (0.7) 641 (5.3) 0.001
OAC 302 (9.5) 448 (3.7) 0.001
SAPT 162 (4.8) 518 (4.3) 0.217
DAPT 3,152 (93.4) 11,394 (94.8) 0.002
Triple therapy 260 (7.7) 335 (2.8) 0.001
OAC only 14 (0.4) 23 (0.2) 0.027
Beta-blockers 2,490 (74.7) 9,785 (82.4) 0.001
ACEI/ARB 2,482 (74.5) 8,591 (75.4) 0.297
Statins 3,015 (89.8) 11,188 (93.9) 0.001
PPI 1,485 (66.2) 4,267 (53.4) 0.001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; OAC, oral
anticoagulant; PPI, proton pump inhibitor; SAPT, single antiplatelet therapy.
Fig. 1 Cumulative incidence of bleeding according to age sub-
groups.
Fig. 2 Post-discharge bleeding location according to age sub-groups.
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CI, 0.666–0.716], p ¼ 0.001). The ROC curves of the BleeMACS
score for predicting bleeding after discharge in both age sub-
groups are shown in ►Fig. 3. ►Fig. 4 shows the cumulative
incidence of post-discharge bleeding according to the Blee-
MACS categories in young (A) and elderly patients (B).
The ability of the BleeMACS score for predicting the
composite of death or post-discharge bleeding was also
moderately lower in elderly patients (AUC, 0.635 [95% CI,
0.606–0.664] vs. 0.673 [95% CI, 0.647–0.699], p ¼ 0.001).
Prediction of Bleeding in the Elderly
The best model for predicting bleeding in elderly patients
included hypertension, previous bleeding, haemoglobin at
admission and previous heart failure. This model showed an
Table 4 Clinical characteristics and in-hospital clinical course according to post-discharge bleeding status in elderly patients
Bleeding post-discharge
(n ¼ 190)
No bleeding
(n ¼ 3,186)
p-Value
Continent 0.958
Europe 137 (72.1) 2,334 (73.2)
Asia 24 (12.6) 397 (12.5)
North America 28 (14.7) 437 (13.7)
South America 1 (0.5) 18 (0.6)
Age 80.6 (4) 80.6 (4) 0.939
Male sex 120 (63.2) 1,882 (59.1) 0.288
Hypertension 154 (81.1) 2,321 (72.8) 0.013
Diabetes mellitus 55 (28.9) 926 (29.1) 0.972
Dyslipidaemia 93 (49.2) 1,504 (47.5) 0.643
Previous MI 31 (16.3) 493 (15.5) 0.756
Previous PCI 30 (15.9) 464 (14.6) 0.644
Previous CABG 6 (3.2) 16 (5.2) 0.217
Previous stroke 20 (10.5) 364 (11.4) 0.705
PAD 30 (15.8) 296 (9.3) 0.003
CHF 21 (12.1) 181 (6.3) 0.003
Malignancy 31 (16.3) 352 (11) 0.026
Previous bleeding 29 (15.4) 231 (7.3) 0.001
LVEF 52 (12) 52 (12) 0.594
Haemoglobin at admission 12.2 (2) 13.1(2) 0.001
Haemoglobin at discharge 11.3 (2) 11.9(2) 0.001
Creatinine at admission 1.28 (1) 1.06 (0.6) 0.002
STEMI 103 (54.2) 1,568 (49.2) 0.181
UA 21 (11.1) 463 (14.5) 0.184
Signs of congestive heart failure 44 (28) 587 (22) 0.077
Femoral access 105 (63.6) 1,660 (59.7) 0.320
Multi-vessel disease 73 (53.3) 1,351 (57.7) 0.311
DES 66 (34.7) 1,087 (34.1) 0.861
Thrombolysis 3 (1.6) 26 (0.8) 0.222
Complete revascularization 76 (50.3) 1,326 (52.7) 0.574
In-hospital bleeding 58 (30.5) 307 (9.6) 0.001
In-hospital transfusion 37 (20.7) 176 (5.8) 0.001
In-hospital reinfarction 6 (3.2) 53 (1.7) 0.127
In-hospital heart failure 19 (11) 190 (6.7) 0.027
BleeMACS score 25 (15) 15 (12) 0.001
Abbreviations: BleeMACS score, Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome score;
CABG, coronary artery bypass grafting; CHF, congestive heart failure; DES, drug eluting stents; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina.
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acceptable predictive ability (AUC, 0.666 [95% CI, 0.62–
0.712]), without significant differences as compared with
the BleeMACS score (p ¼ 0.276).
Finally, ►Table 6 shows the specific contribution of each
component of the BleeMACS score for predicting post-dis-
charge bleeding according to age. The contribution of age,
vascular disease and malignancy was not statistically sig-
nificant in elderly patients. In contrast, the predictive role of
hypertension, previous bleeding, renal function and haemo-
globin levels remained significant in both sub-groups.
Discussion
The main findings from our study are: (1) elderly patients
from this series patients had a moderately higher incidence
of serious spontaneous bleeding at 1 year and a shorter time
to bleeding episodes, without significant differences regard-
ing bleeding location; and (2) despite a moderately lower
predictive ability in patients at older ages, the BleeMACS
score showed an acceptable performance in these patients.
Haemorrhagic complications are associated with a higher
mortality in patients with ACS, especially in the elderly.16–18
Current guidelines establish a reference standard duration of
DAPTof 12 months.2However, recent evidence suggests that
treatment with DAPT beyond the first year may be beneficial
in selected groups of patients with low bleeding risk,19
particularly when the ischaemic risk is high.20 On the other
hand, guidelines state that shorter DAPT regimens may be
considered in patients deemed at high bleeding risk.2 There-
fore, bleeding risk is one of the main factors in choosing the
type and duration of antiplatelet therapy after an ACS.
Several bleeding risk scores havebeendevelopedandwidely
used forpredictingmajor in-hospitalbleeding.5–7Theserecom-
mended risk scores seem to not adequately predict post-dis-
charge bleeding in patientswith ACS.21 Thebleeding profile for
in-hospitalphase(predominanceofaccesssitebleeding, related
with the coronary intervention and parenteral antithrombotic
drugs) is clearly different than for post-discharge period (pre-
dominance of gastrointestinal bleeding, related with oral anti-
platelet therapy).22–24 Recent studies have demonstrated that
bleeding after discharge is also associated with a significant
increase in the risk of death and myocardial infarction.25–27
Available information about the prediction of bleeding after
discharge in patients with ACS is scarce.
Baber et al19 developed a risk score for predicting major
bleeding at 2 years in 4,190patients undergoing successful PCI
with stent implantation from the PARIS registry. Independent
predictors of bleeding included older age, body mass index,
triple therapy at discharge, anaemia, current smoking and
renal dysfunction, and the predictivemodel showed an accep-
tableability for predictingmajorbleeding. Ina sub-studyof the
Table 5 Post-discharge treatment according to post-discharge bleeding status in elderly patients
Bleeding at discharge
(n ¼ 190)
No bleeding
(n ¼ 3,186)
p-Value
Aspirin 189 (99.5) 3,123 (98) 0.154
Clopidogrel 162 (85.3) 2,909 (91.3) 0.005
Ticagrelor 13 (6.8) 94 (3) 0.003
Prasugrel 1 (0.5) 23 (0.7) 0.755
OAC 23 (12.1) 299 (9.4) 0.215
SAPT 12 (6.3) 150 (4.7) 0.314
DAPT 175 (92.1) 2,977 (93.4) 0.473
Triple therapy 20 (10.5) 240 (7.5) 0.133
OAC only 0 14 (0.4) 0.360
Beta-blockers 134 (70.9) 2,356 (74.9) 0.215
ACEI/ARB 142 (75.1) 2,340 (74.4) 0.829
Statins 173 (91.5) 2,842 (89.7) 0.420
PPI 93 (71.5) 1,392 (65.9) 0.188
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; OAC, oral
anticoagulant; PPI, proton pump inhibitor; SAPT, single antiplatelet therapy.
Fig. 3 Receiver-operating characteristic (ROC) curves for the prediction of
post-discharge bleeding by the BleeMACS (Bleeding complications in a
Multicenter registry of patients discharged with diagnosis of Acute
Coronary Syndrome) score according to age sub-groups.
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DAPT trial, Yeh et al20 derived a risk score for predicting
ischaemic and bleeding events in 11,648 patients not sustain-
ing major bleeding or ischaemic events 1 year after PCI. The
predictors included in themodelweremyocardial infarctionat
presentation, priormyocardial infarctionorPCI, diabetes, stent
diameter < 3 mm, smoking, paclitaxel-eluting stent, history
of congestive heart failure/low ejection fraction, vein graft
intervention and age. Derivation cohort model predicting
bleeding events had c-statistics of 0.68.
More recently, Costa et al28 studied a series of 14,963
patients treated with DAPT after coronary stenting from
eight multicentre randomized clinical trials. A predictive
score for out-of-hospital thrombolysis in myocardial infarc-
tion (TIMI) major or minor bleeding was derivated from this
series. This score (so-called PRECISE-DAPT score) included
age, creatinine clearance, haemoglobin, white blood cell
count and previous spontaneous bleeding, and showed a
c-index for out-of-hospital bleeding of 0.73. This score was
validated in patients treated with PCI from the PLATelet
inhibition and patient Outcomes (PLATO) trial (c-statistic
of 0.70) and BernPCI registry (c-statistic of 0.66).
It is important to note that patients included in these
studies were at relatively low bleeding risk, since more than
60% of patients from the PARIS registry19 underwent PCI for
stable angina, and in a not negligible proportion of patients
included in the PRECISE-DAPTscore and in the DAPTstudy,20
the reason for performing PCI was not an ACS. In addition,
patients suffering bleeding events during the first 12months
on DAPT and patients requiring oral anticoagulation were
not included in the DAPT study.
Fig. 4 Cumulative incidence of bleeding according to the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged
with diagnosis of Acute Coronary Syndrome) score categories in young patients (A) and elderly patients (B).
Table 6 Contribution of each predictor of the BleeMACS score according to age sub-groups
Younger patients Elderly patients
Predictor sHR (95% CI) p-Value sHR (95% CI) p-Value
Age (per y) 1.03 (1.02–1.05) 0.001 1 (0.98–1.02) 0.390
Hypertension 1.30 (0.99–169) 0.053 1.49 (1.01–2.20) 0.045
Vascular disease 1.49 (1.07–2.07) 0.017 1.18 (0.83–1.69) 0.351
History of bleeding 1.49 (0,96–2.32) 0.074 2.12 (1.41–3.19) 0.001
Malignancy 1.81 (1.21–2.69) 0.003 1.35 (0.92–1.99) 0.130
Creatinine (g/dL) 0.065 0.005
< 1.0 Ref Ref
1–1.49 1.05 (0.79–1.41) 1.43 (1.02–2.01)
> 1.5 1.59 (0.97–2.59) 1.82 (1.20–2.75)
Haemoglobin (g/dL) 0.001 0.001
< 11.0 2.65 (1.69–4.17) 2.71 (1.71–4.32)
11–13.9 1.28 (0.98–1.65) 1.49 (1.01–2.21)
> 14.0 Ref Ref
Abbreviations: BleeMACS score, Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome
score; CI, confidence interval; sHR, sub-hazard ratio.
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The BleeMACS score8 was the first risk score designed to
estimate the probability of developing a serious haemorrha-
gic event within the first year after hospital discharge for an
ACS. The score was developed in an extensive series of all
corners ACS patients from routine clinical practice, obtaining
a good predictive ability in this clinical setting.
Ontheotherhand, the incidenceofACSisparticularlyhigh in
the elderly, and the number of elderly patients who are
hospitalized for ACS is increasing.9,10 These patients are at
increased risk both for ischaemic and bleeding complications.
However, information about the real incidence of post-dis-
charge bleeding in non-selected elderly patientswith ACS from
routineclinical practice isscarce.Data fromthis series showeda
higher incidence of post-discharge bleeding in elderly patients.
However, this increase of riskwasmoderate, despite the clearly
higher prevalence of comorbidities of patients at older ages.
On theotherhand, apoorer abilityof the recommendedrisk
scores for predicting in-hospital bleeding in elderly patients
with ACS has previously been reported.12,29,30 The prediction
of bleeding after discharge in patients at older ages is also an
important issue, since the antithrombotic management of
these patients is often complex, due to a more severe and
complex coronary artery disease, higher prevalence of comor-
bidities and more common concomitant indication of oral
anticoagulants because of conditions such as atrial fibrillation
or previous stroke. To date, no study assessed the prediction of
post-discharge bleeding episodes in elderly patients with ACS.
The ability of the BleeMACS score for predicting post-
discharge bleeding was lower in patients aged 75 years or
older from this series. However, this loss of performance was
moderate, in contrast to other studies assessing in-hospital
bleeding risk in elderly patients.12 The lower predictive ability
observed in elderly patients from our study could be mostly
due to the fact that age accounts formore than 10% of points of
the total score. Despite this, in our opinion the BleeMACS score
exhibited an acceptable performance also in elderly patients.
In fact, the predictive model specifically performed in elderly
patients did not significantly improve the prediction of bleed-
ing as compared with the BleeMACS score.
Interestingly, the predictive role of each of the compo-
nents of the score differed according to age. While several
predictors remained significant or increased its level of
significance in the elderly (renal function, haemoglobin,
hypertension, previous bleeding), others reduced its predic-
tive contribution to the model (age, vascular disease, malig-
nancy). A different antithrombotic management in patients
with these conditions or different types of neoplasm at older
ages (not so aggressive or with a lower likelihood for bleed-
ing) may partially explain these findings. However, the type
of neoplasm was not recorded in the BleeMACS database, so
these data should be confirmed in other populations.
Aging is a heterogeneous process and risk assessment in
elderlypatientsmightbeconditionedby thepresenceof frailty
and other aging-related variables.31–33 Recent data suggest a
modest contribution of a comprehensive geriatric assessment
for predicting in-hospital bleeding in elderly patients with
ACS.34 However, the role of these variables for predicting
bleeding after discharge could be more important.
This article has several limitations. The BleeMACS score
was derived from a cohort of a retrospective registry, carry-
ing the limitations inherent to this type of studies. Changes in
antithrombotic therapy were not assessed, such as switch
between antiplatelet drugs or DAPT discontinuation. On the
other hand, information about frailty, disability and other
aging-related variables was not available. However, despite
these limitations we believe that this article retrieves novel
and important data about characteristics and prediction of
bleeding complications after discharge in elderly patients
with ACS from routine clinical practice.
Conclusions
Elderly patients from this series had a moderately higher
incidence of post-discharge bleeding. In spite of a moderate
lossofpredictive ability inpatientsatolderages, theBleeMACS
exhibited an acceptable performance also in these patients.
What is known about this topic?
• Elderly patients are at higher risk for ischaemic and
bleeding complications, prolonged hospital stay and
increased consumption of health resources.
• The elderly are poorly represented in clinical trials and
registries from whom currently recommended bleed-
ing risk scores were developed. A poorer ability of
these risk scores for predicting in-hospital bleeding
has been reported in elderly patients with ACS.
• Information about prediction of post-discharge bleed-
ing is scarce. The BleeMACS score exhibited a good
ability for predicting serious bleeding 1 year after
discharge in non-selected patients with ACS. No study
assessed the prediction of post-discharge bleeding in
elderly patients with ACS.
What does this paper add?
• In this extensive series (n ¼ 15,401) of ACS patients,
patients aged 75 years (21.9%) weremore commonly
treated with clopidogrel and less often treated with
ticagrelor or prasugrel. A total of 489/15,401 patients
(3.2%) presented serious spontaneous bleeding at
1 year. The incidence of bleeding was moderately
higher in elderly patients (HR, 2.31, 95% CI, 1.92–
2.77, p < 0.001).
• Mean time to bleeding episodes was significantly
shorter in the elderly (134 vs. 159 days, p < 0.001),
without significant differences regarding bleeding
location according to age.
• Despite amoderate loss of predictive ability in patients
at older ages (AUC, 0.652 vs. 0.691, p ¼ 0.001), the
BleeMACS score exhibited an acceptable performance
also in the elderly. The specific contribution of each of
the components of the scorewas significantly different
according to age.
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